Skip to NavigationSkip to content

Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

Published on 14/04/20 at 12:32pm
Photo by A4

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company's patents.

In December, a California jury decided to award Bristol-Myers Squibb $752 million regarding Gilead’s CAR-T treatment Yescarta. Gilead had acquired Kite Pharma in 2017 to gain Yescarta, and Bristol-Myers Squibb alleged the treatment's development was based on a patent owned by Juno therapeutics, that BMS acquired in 2018.

As a result of the new ruling, US District Judge Philip S. Gutierrez boosted the amount Gilead owes BMS from $752 million to $1.2 billion. This additional cost is labelled as “enhanced damages.”

Gilead plans to appeal the verdict and told the Times it believes that the ruling is legally “unsupportable” and the company believes it will be reversed. They maintain that Kite developed Yescarta independently and did not infringe on the Juno’s patent.

Yescarta was first approved by the FDA in 2017, and was the first CAR-T treatment for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches